Innovent Expands Internationally With Indonesia Deal
Licensing Agreement Reached With Etana For Byvasda Bevacizumab Biosimilar
Innovent Biologics has broadened its international reach by striking a licensing deal with PT Etana Biotechnologies in Indonesia for its Byvasda bevacizumab biosimilar.
You may also be interested in...
Innovent and marketing partner Etana have celebrated an approval for their Bevagen bevacizumab biosimilar from the Indonesian regulator.
Plus deals involving Helixmith/Wacker, Sosei Heptares/Metrion, Ono/Ribon, Asahi Kasei/Lilly, Citrine/Diurnal, Mitsubishi Tanabe/Aquestive, Immunotech/T-Cure, TRIGR/Elpiscience, Daiichi Sankyo/ViGeneron
Chinese biotech specialist Innovent Biologics has received approval for new indications for its adalimumab and bevacizumab biosimilars from China’s NMPA.